Introduction
Antiepileptic medications (AEDs) remain the mainstay of treatment in epilepsy. Currently, over 20 FDA-approved AEDs are available for use in management of patients with epilepsy. Adverse effects resulting from AEDs are common. The impact of adverse effects on the overall health, as assessed with quality of life (QOL) scales, is significant, with adverse medication effects having the strongest correlation with health-related QOL in one study [1] . Among a number of potential adverse effects that can result from the use of AEDs, subjective cognitive side effects (CSEs) may necessitate either discontinuation or dose reduction if symptoms are felt to be intolerable.
In a previous study by our group [2] , we examined the prevalence of CSEs among commonly used AEDs and the potential predictors of CSEs among 1694 adult epilepsy patients followed at a single tertiary care center between 2000 and 2005. Since our previous paper, several new AEDs have been approved by the FDA. The newly approved AEDs include lacosamide, pregabalin, rufinamide, vigabatrin and clobazam (although the latter two were included in the prior study via importation from other countries). Also, some medications have become much more popular, such as levetiracetam [3] . Although some studies indicate that the risk of CSEs of the newly approved AEDs may be favorable [4, 5] , few data exist on comparison of CSEs of these new AEDs against all available AEDs.
We herein report an extended follow-up of our prior study, adding 1166 patients and 3 new AEDs with follow-up data up to year 2012 (7 years later than the prior study). We examined the relative frequency of CSEs attributed to specific AEDs, including the 5 recently approved AEDs. We also investigated the non-AED predictors of CSEs. With longer follow-up, more patients, and inclusion of 5 new AEDs, this study provides a more comprehensive picture of current clinical experience regarding AED-related subjective CSEs.
Materials and methods
Methodology was similar to that of our prior publication [2] . We reviewed the medical charts of 2860 adult (at least 16 years of age at first visit) outpatients seen by their treating epilepsy attending at the Columbia Comprehensive Epilepsy Center between January 1, 2000 and November 19, 2012 and with outcome available for at least one AED trial. During the 12-year study period, of the 2860 patients, 2192 patients were started on one or more AEDs at our center. AEDs started for the first time at our center were classified as ''newly started'' AEDs (carbamazepine [CBZ] Documentation of CSEs that developed during the use of any AED was obtained by review of all available notes in the medical chart, including review of a symptom checklist completed at each visit, telephone notes, and physician notes. Attribution of subjective CSEs to a particular AED was made based on physician notes. Cognitive side effects were categorized as one of the following: (1) language problems such as aphasia, anomia/wordfinding difficulty, (2) memory difficulty, or (3) psychomotor/ cognitive slowing, confusion/disorientation or encephalopathy. ''Intolerable'' CSEs (ICSEs) were defined as CSEs attributed to an AED resulting in dose reduction or discontinuation of that AED. In the situation of multiple concomitant AEDs, CSE attribution to an AED was made only if the medical chart specified an AED.
Data abstraction based on review of medical records included patient characteristics including medical and psychiatric history, concomitant medications and dosages, laboratory test results, side effects, and efficacy measures. Data were entered into an electronic database by trained research assistants. As there was one person entering data per patient medical record, no inter-rater reliability was evaluated. However, on a regular basis, the physician investigator performed random review of data entered by all research assistants. Additionally, automatic error reports were generated, for example, highlighting inconsistencies between syndrome and seizure type. Other possible errors were detected, such as flags for ''outlier'' doses and serum levels that fell more than 2 SD from the mean. These were then manually checked for accuracy.
Predictor analysis
To investigate potential non-AED predictors of ICSEs, we examined 77 variables (Supplementary Table 1) , which included various demographics, medical and psychiatric history, and epilepsy-related variables. To evaluate the possible predictors of ICSEs, we first performed univariate analysis using a simple logistic regression model to predict the occurrence of ICSEs. All variables found to be associated with ICSE in the univairate model with an a 0.1 level were then fit in the multiple logistic regression analysis using ''enter'' selection method (with an a 0.05). The multiple logistic regression analysis, allowed us to test for associations between each variable controlling for other variables in the model and to investigate the extent to which these variables explained the observed between-patient variation in ICSE. Significance for multiple logistic regression analysis was set at p < 0.003 (based on Bonferroni correction of p = 0.05/17). The denominator of 17 represents the number of significant variables that were included in the final multiple logistic regression analysis.
Drug comparison
We investigated the frequency of ICSEs attributed to a newly started AED. We compared the rates of AED-related ICSEs among (a) 1871 patients with AEDs newly started as part of polytherapy, and (b) 1243 patients who were started for the first time on specific AEDs as monotherapy (may or may not be drug naïve at the time of initiation of these AEDs) at our center. We also examined whether the occurrence of ICSEs was related to differences in AED dose load (i.e., dosage). First, AED load was calculated for each individual patient by dividing the AED dose at the time of ICSE by the defined daily dose (DDD) of that particular AED [6] . The DDD is the maintenance dose of an AED used for its main indication in adults considered by the World Health Organization (WHO) [7] . The DDD values are listed in Supplementary Table 8 . As an example, the AED load for a patient on 400 mg of medication X at the time of ICSE would be calculated as 400 mg divided by the DDD of medication X. If the DDD was 200 mg, the AED load would equal 2. Then, for each AED, we compared the mean AED load of patients with ICSE with that of patients without ICSE for that particular AED, using one-way analysis of variance (ANOVA).
All analyses were conducted with IBM SPSS Statistics V19 (Chicago, IL).
Results
Briefly, the demographics and characteristics of the 2860 patients (Table 1 ) included a mean age of 40.6 years. The majority of patients (71%) had focal epilepsy. Patients tried an average of 3.5 distinct drug combinations and stayed on an AED for a median duration of 40 months.
Of the entire cohort (n = 2860), 428 (15.0%) patients had intolerable CSEs (ICSEs) attributed to at least one AED. Among 1871 patients who were newly started on an AED in polytherapy, 210 patients (11.2%) had ICSEs. Among the 1243 patients who were newly started on an AED in monotherapy, 94 patients (7.6%) had ICSEs. The number of patients who tried each AED, frequency of AED use by epilepsy type, and mean maximum dose for each AED (Table 1) were indicative of the practice pattern at this single site on a group level.
Predictors of ICSEs
In the univariate analysis comparing the occurrence of ICSE and each independent variable individually, we found significant associations between ICSE and 17 variables (as listed in Table 2) .
A multiple logistic regression model was then fit to determine independent non-AED predictors of ICSEs, including all factors that were found to be associated with the outcome with p < 0.1 in univariate analysis. To address the issue of multiple comparisons, we set the p value for significance in multivariate analysis at p < 0.003 (based on Bonferroni correction), with the p value for ''trend'' as 0.003 < p < 0.05 [8] . Intellectual disability (OR = 0.42, p = 0.001), and use of AED in polytherapy (OR = 3.41, p < 0.001) were found to be significantly associated with ICSEs (with intellectual disability being ''protective''), controlling for the other factors in the model ( Table 2 ). All of the variables significant in univariate and tested in multivariate analyses are presented in Table 2 . Nagelkerke R 2 on the model level was 0.07, indicating that the model accounts for only 7% of the variability in the dependent variable.
Comparison of ICSE rates for specific AEDs
We compared the relative rates of ICSEs associated with each when AEDs were newly started as part of polytherapy (Supplementary Table 2 and Supplementary Figure 1 ), and relative rates of ICSEs when AEDs were newly started in monotherapy (Supplementary Table 3 and Supplementary Figure 2) . We repeated the analysis, examining the rate among those without intellectual disability (Supplementary Table 4 ).
Relative rates of ICSEs from newly started AEDs in polytherapy
When examining the rate of ICSEs associated with newly started AEDs (when AEDs were part of polytherapy), the highest rate of ICSEs occurred with TPM (22.8%) ( Table 3) . When TPM was compared against other AEDs in head-to-head comparison (Supplementary Table 2 ), the rate of CSEs intolerability from TPM was significantly higher (p 0.001) than all AEDs except PB, PRM, and TGB. Among the newer AEDs, TGB and ZNS had the next highest rate of CSEs (15.4% and 8.6%, respectively).
As seen in Table 3 , no ICSEs were reported with VGB, although only 38 patients took VGB (in polytherapy). With the exception of VGB, LTG was associated with the lowest ICSEs (2.5%) when LTG was newly started as part of polytherapy. When LTG was compared against other AEDs in head-to-head comparison, the rate of ICSEs from LTG (2.5%) was significantly lower than those of PRM (15%, p = 0.001), TGB (15.4%, p = 0.005), VPA (6.3%, p = 0.004), ZNS (8.6%, p < 0.001) and TPM (22.8%, p < 0.001). Between ZNS and LEV, two commonly prescribed newer AEDs, ZNS (8.6%) had a significantly higher rate of ICSEs when compared with LEV (4.2%, p = 0.002).
As seen in Table 4 , when TPM was newly started as part of polytherapy, it was 6.2 times more likely to be associated with ICSEs than all other polytherapy regimens combined (p < 0.0001).
ZNS was 1.65 times more likely to be associated with ICSEs compared to other polytherapy regimens combined (p = 0.008). In contrast, LEV and LTG were less likely to be associated with ICSEs when compared to other polytherapy that did not include either LEV (OR = 0.68, p = 0.04) or LTG (OR = 0.37, p < 0.0001).
Relative rates of ICSEs from AEDs newly started and in monotherapy
The rates for ICSEs associated with AEDs newly started and in monotherapy are shown (Table 3) . TPM had the highest rate of ICSEs (18.5%), followed by PHT (11%). When compared against other AEDs in head-to-head comparison (Supplementary Table  3 ), the rate of CSE intolerability from TPM (18.5%) was higher than that associated with CBZ (3.6%, p = 0.001), GBP (2.5%, p = 0.003), LEV (5.5%, p = 0.003) and LTG (4.7%, p < 0.001). The rate of ICSEs with PHT was significantly higher than with GBP, CBZ, and LTG. As in Table 5 , patients on TPM monotherapy were 3.7 times more likely to experience ICSEs compared to all other monotherapy regimens combined (p = 0.001). Patients on LTG monotherapy were 37% less likely to report ICSEs (OR = 0.63, p = 0.04), when compared to all other monotherapy trials combined; rates were also low (but not significant) with GBP, PGB, CBZ AND LEV.
Relative rates of ICSEs from AEDs newly started and in monotherapy, stratified by intellectual disability
When limiting the analysis to patients without intellectual disability who had newly started AED as monotherapy (n = 1202 in Supplementary Table 4), TPM again had the highest rate of ICSEs, followed by PHT; GBP, PGB, and CBZ had the lowest rates of ICSEs. Because only 41 patients with intellectual disability had newly started an AED as monotherapy (with only 1 patient having ICSE), we did not perform head to head comparison between AEDs.
Types of ICSEs
The frequencies of specific types of ICSEs associated with each AED are shown in Table 6 . Similar to what we found in our previous investigation, the most frequent specific ICSE associated with TPM was psychomotor/cognitive slowing (13.7%). 
Timing of ICSEs
Supplementary Tables 5 and 6 list the frequency of ICSEs that occurred during the AED titration period, which we defined as the first 8 weeks after initiation of an AED. Supplementary Tables 5 and  6 show data on percent of patients who had CSE attributed to AED, percent of patients who had intolerable CSE, percent of patients who had intolerable CSE during titration period (first 8 weeks of starting an AED), as well as those who discontinued versus those who reduced AED dose but continued. The last group who continued AED after reducing the dosage presumably had sufficient amelioration of cognitive condition and worthwhile improvement in seizure control. For example, of 79 patients who newly started GBP as monotherapy, 2.5% had intolerable CSE. Only 1.3% discontinued GBP, while 1.2% reduced GBP dose and continued it. On the other hand, of 54 patients who newly started TPM as monotherapy, 18.5% had ICSE. Most of those patients discontinued (14.8%) TPM, while 3.7% chose to continue TPM.
Of those with ICSE, relatively small number of them reduced the AED dose. For example, 22.8% of 281 patients on TPM as part of polytherapy had ICSEs, with 22.1% discontinuing TPM while 0.7% reduced their TPM dose.
Effect of dose on ICSE
As seen in Supplementary Table 7 , AED load did not differ significantly between patients with ICSE and patients without ICSE for most AEDs. For VPA and ZNS, AED load was significantly lower in patients with ICSE than patients without intolerable CSE.
Discussion
In the present study we identified two predictors of intolerable CSEs (ICSEs): lack of intellectual disability and use of AEDs in polytherapy. Patients with intellectual disability, as assessed by the treating epilepsy attendings, were less likely to report CSEs than patients without intellectual disability, controlling for other potential predictors in the model. This may be reflective of difficulty detecting additional cognitive impairment in cognitively disabled patients, likely related to underreporting by patients.
The rates of CSE profiles differed between AEDs. The highest rate of ICSEs occurred with TPM, whether TPM was newly started as part of a polytherapy or in monotherapy. When polytherapy contained TPM as a newly started AED, it was six times more likely to be associated with CSEs compared to polytherapy regimens that did not include TPM. Monotherapy with TPM as a newly started AED was 3.7 times more likely to be associated with CSEs than all other newly started AEDs in monotherapy. Treatment-emergent cognitive effects of TPM have been shown in a number of doubleblind placebo controlled trials, retrospective studies, metaanalyses and post-marketing reports [2, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . Investigations directly comparing TPM to other AEDs performed in both epilepsy and healthy subjects support our findings, showing TPM results in significantly more CSEs than GBP, LEV, LTG or VPA [25] [26] [27] [28] [29] [30] [31] . To our knowledge, no other study has shown direct comparison of TPM to most of the newly approved AEDs. Next, PHT had the second highest rate of CSEs in monotherapy (11% of 100 patients). Additionally, compared to other newer AEDs such as LEV and LTG, ZNS was significantly more likely to be associated with CSEs when newly started in polytherapy. In the literature, language impairment was present in two pilot studies while a single long-term prospective study showed 47% experienced delayed word recall on ZNS after one year on monotherapy [32] [33] [34] . LTG, when used in polytherapy, was less likely to be associated with CSEs compared to all other polytherapy regimens combined. Monotherapy of LTG was about a third less likely to be associated with CSEs compared to all other monotherapy combined. In two prospective clinical trials, no CSEs were observed with LTG therapy [35, 36] . Notably, GBP, PGB, and CBZ had low or lower rates of CSE than LTG, although not statistically significant. One reason for the lack of significant association could be due to number of patients taking these AEDs. Also note that the rate of CSEs associated with OXC in monotherapy was higher than that for CBZ, approaching significance (p = 0.07) ( Table 5 ).
Since our previous study, a number of new AEDs have been FDA approved for seizure control. These include LCM, PGB, VGB, CLB, and RFM. Cognitive impairment was infrequently reported when LCM was used as part of polytherapy. In agreement with our findings, randomized controlled trials did not show clear cognitive impairment with LCM [37] , while one retrospective study in outpatients with epilepsy showed LCM's CSE profile to be comparable to LTG [38] . None of 38 patients newly started on VGB as part of polytherapy in our study had intolerable CSEs. In prior studies in which VGB was compared to placebo, no significant difference in CSEs was found [39] [40] [41] . It is important to note that the absence of CSE among 38 patients may have been confounded by intellectual disability. Sixteen out of 38 patients on VGB had intellectual disability, which may have made detection of CSE more difficult. Even if VGB has a low rate of CSE, the benefit of VGB will have to be weighed against the risk of irreversible visual field restrictions associated with VGB [42] .
Studies examining tolerability of CLB have focused on pediatric populations or adults with Lennox-Gastaut syndrome [4, [43] [44] [45] [46] . These studies suggest that little to no cognitive impairment is associated with CLB. Since patients with intellectual disability are less likely to report ICSEs, rate of ICSEs from CLB in other patient population (i.e., those without intellectual disability) remains unclear. In our study, ICSEs were relatively rare with CLB in polytherapy. Similarly, much of the data on RFM is limited to patients with Lennox-Gastaut syndrome.
Cognitive slowing was the most frequently cited type of ICSE for TPM among our patients. Although marked cognitive slowing has been associated with TPM [29] , other studies have also reported a reduction in verbal IQ, deterioration in verbal fluency and comprehension when assessed with neuropsychological testing [24, 47] , which we did not test. We report the rates of CSE attributed to an AED, the rates of ICSE, and the number of patients with ICSE who discontinued the AED. While the majority of patients experiencing ICSE chose to discontinue the AED, we postulate that the patients with ICSE who reduced their dose (instead of discontinuing the AED) felt that there was a worthwhile improvement of seizure control to continue the AED.
There are some notable limitations in this study. First, this was a retrospective study of adult outpatients. Thus, these results are not neither generalizable to all epilepsy patients nor applicable to children with epilepsy. To minimize the effect of recall bias, we included only AEDs newly started at our center. Second, the occurrence of CSEs and attribution to a newly started AED was based on patient report and physician judgment. Among patients with refractory epilepsy, ''memory difficulties'' are a common complaint [48] . Therefore, it is difficult to disentangle cognitive side effect of a medication from cognitive dysfunction resulting from refractory epilepsy among such patients. We relied on subjective complaints of patients which were deemed by the treating physician to be related to a newly started AED. As highlighted in a recent publication by Witt and Helmstaedter [49] , cognitive monitoring with objective and validated neuropsychological measures may be feasible and will likely improve care of patients. However, a systematic approach of assessing cognitive function before and after the introduction of an AED with validated instrument has not been incorporated in clinical practice. Third, CSE reporting might have differed depending on patient expectations or physician bias. For example, patients who were provided with the expectation of possible CSEs may have been more likely to report CSEs after initiating an AED than patients who were reassured about the small likelihood of possible CSEs. In addition, it is very difficult if not impossible to account for physician bias when blaming a given AED in patients on polytherapy. However, the monotherapy results were very similar to the polytherapy results, and the large number of physicians involved should reduce this bias. Fourth, some AEDs were infrequently used (e.g., TGB, VGB, RFM, and PRM), so the sample size of patients varied across different drugs (Table 1 ), making it difficult to detect CSEs in infrequently used AEDs. Lastly, possibility existed that patients with ICSE could have been on higher doses of AED than patients without ICSE. One way to address this issue was by comparing the AED load, calculated as AED dose at time of side effect divided by WHO defined daily dose of that medication, between patients with and without ICSE. No significant differences in AED load was found between patients with and without ICSE. We also provided the average maximum dose used for each AED, reflecting a local practice pattern among the treating physicians at our study site (Table 1) .
Despite these limitations, the method of ascertainment of CSEs in the current study is similar to the manner in which CSEs are determined in routine daily care of patients with epilepsy; any CSEs bothersome enough for the patient to report to their physician were in fact documented and thus reported in this study. Thus, the results should be directly applicable to clinical practice.
The strength of this study is that we were able to examine the occurrence of CSEs for almost all FDA-approved AEDs and compare the relative rates among them in a large cohort of outpatients with epilepsy. Although a randomized, double-blinded trial comparing all the AEDs with standard dosing would be ideal to determine the difference in CSEs, such a study would be prohibitively large and expensive.
Conclusion
Our results suggest that TPM was most likely to be associated with intolerable CSEs when used in poly-or monotherapy. Not surprisingly, use of AED in polytherapy was a significant predictor of intolerable CSEs. Patients with intellectual disability were less likely to report CSEs. Additionally, ICSEs tended to occur outside the window of AED titration period and did not necessarily occur as a result of patients taking a higher dose of AED.
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